Maren Darsow

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

Long-Term Morbidity Following Axillary Dissection in Breast Cancer Patients – Clinical Assessment, Significance for Life Quality and the Impact of Demographic, Oncologic and Therapeutic Factors

Thorsten Kuehn, Wolfgang Klauss, Maren Darsow et al. · Breast Cancer Research and Treatment · 2000 · 232 citations

Surgical Oncology, Breast Oncology, Medicine +8

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

Ulrike Nitz, Oleg Gluz, Hans Kreipe et al. · Therapeutic Advances in Medical Oncology · 2020 · 44 citations · Full text

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2− trial

Oleg Gluz, Sherko Küemmel, Ulrike Nitz et al. · Annals of Oncology · 2023 · 16 citations · Full text

Breast Oncology, Oncology, Wsg-adapt-hr+/her2− Trial +8

Abstract GS4-04: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2- trial

Nadia Harbeck, Oleg Gluz, Sherko Küemmel et al. · Cancer Research · 2021 · 12 citations

Breast Oncology, Recurrence Score, Excellent Prognosis +19